Shared and separate functions of polo-like kinases and aurora kinases in cancer
The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Abstract
Large numbers of inhibitors for polo-like kinases and aurora kinases are currently being evaluated as anticancer drugs. Interest in these drugs is fuelled by the idea that these kinases have unique functions in mitosis. Within the polo-like kinase family, the emphasis for targeted therapies has been on polo-like kinase 1 (PLK1), and in the aurora kinase family drugs have been developed to specifically target aurora kinase A (AURKA; also known as STK6) and/or aurora kinase B (AURKB; also known as STK12). Information on the selectivity of these compounds in vivo is limited, but it is likely that off-target effects within the same kinase families will affect efficacy and toxicity profiles. In addition, it is becoming clear that interplay between polo-like kinases and aurora kinases is much more extensive than initially anticipated, and that both kinase families are important factors in the response to classical chemotherapeutics that damage the genome or the mitotic spindle. In this Review we discuss the implications of these novel insights on the clinical applicability of polo-like kinase and aurora kinase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, some kinases and phosphatases simultaneously hit the same kinesins to tune the balance between phosphorylation and dephosphorylation to modulate activity or spindle targeting [56, 57].”
From Regulatory mechanisms that control mitotic kinesins (2015) · cites this paper as [56]
Citations
Cites
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000 · cited 1×
“Well-known examples of these drugs are those that perturb the formation of the mitotic spindle such as taxanes and vinca alkaloids”
BackgroundEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
The anaphase promoting complex/cyclosome: a machine designed to destroy
Peters, J.-M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1988 · Cited by 1,315 · cited 1×
“Once proper chromosome alignment is established, cyclin B and securin are degraded by the anaphase-promoting complex/cyclosome bound to CDC20 (APC/C CDC20”
BackgroundTyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundTumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
Bischoff, J. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3052 · Cited by 1,216 · cited 1×
“Oncogenic activity Overexpression of aurora kinase A induces oncogenic transformation in immortalized rodent fibroblast”
BackgroundDitchfield, C., Johnson, V. L., Tighe, A., Ellston, R., Haworth, C., Johnson, T., Mortlock, A., Keen, N., & Taylor, S. S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208091 · Cited by 1,194 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundHauf, S., Cole, R. W., LaTerra, S., Zimmer, C., Schnapp, G., Walter, R., Heckel, A., van Meel, J., Rieder, C. L., & Peters, J.-M. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208092 · Cited by 1,155 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundA Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · cited 1×
“Most recently, tumour cell lines carrying a KRAS-G13D mutation were shown to be hypersensitive to inhibition of PLK1 (Ref”
Background
Cited by
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
“PP6 negatively regulates levels of the melanoma oncogeneCCND1 during G1 phase of the cell cycle (Stefansson and Brautigan, 2007) and is the major T-loop phosphatase for the mitotic kinase, Aurora A (AurA), which is amplified in a number of human cancers (Lens et al., 2010; Zeng et al., 2010).”
BackgroundThe chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis
Carmena, M., Wheelock, M., Funabiki, H., & Earnshaw, W. C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3474 · Cited by 905
Rath, O., & Kozielski, F. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3310 · Cited by 496
Targeting Mitosis in Cancer: Emerging Strategies
Dominguez-Brauer, C., Thu, K. L., Mason, J. M., Blaser, H., Bray, M. R., & Mak, T. W. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.006 · Cited by 495
“AURKA is amplified in cancers of the breast, ovary, lung, bladder, stomach, pancreas, head-and-neck, and colon, whereas AURKB is overexpressed in breast cancer, NSCLC, glioblastoma, and prostate cancer (Boss et al., 2009; Lens et al., 2010; Malumbres, 2011).”
BackgroundPLK1, A Potential Target for Cancer Therapy
Liu, Z., Sun, Q., & Wang, X. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.10.003 · Cited by 454
“Among them, PLK1 was the most investigated [2].”
BackgroundPlk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Visconti, R., Della Monica, R., & Grieco, D. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0433-9 · Cited by 366
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358
Ferguson, L. R., Chen, H., Collins, A. R., Connell, M., Damia, G., Dasgupta, S., Malhotra, M., Meeker, A. K., Amedei, A., Amin, A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.005 · Cited by 336
“Aurora kinase , for example, detects misattached chromosomes [79,80] and verexpression of the kinase is sufficient to disrupt the checkpoint nd promote tetraploidy [81].”
The aurora kinases in cell cycle and leukemia
Goldenson, B., & Crispino, J. D. (2015) · Oncogene · doi:10.1038/onc.2014.14 · Cited by 334
Mitosis-targeted anti-cancer therapies: where they stand
Chan, K.-S., Koh, C.-G., & Li, H.-Y. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.148 · Cited by 305
“Tumor-specific partial responses have also been reported in clinical trials utilizing drugs directing at these kinases.(23) Aurora B inhibitors, however, work differently at the end of mitosis by disrupting cytokinesis and causing polyploidy cells with restricted viability.”
BackgroundThe Influence of Cell Cycle Regulation on Chemotherapy
Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136923 · Cited by 290
“Polo-like kinase 1 (PLk-1) is a serine-threonine kinase that is involved in mitosis and does not depend on cyclin [148].”
BackgroundImplementing personalized cancer genomics in clinical trials
Simon, R., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 301
From Plk1 to Plk5: Functional evolution of polo-like kinases
de Cárcer, G., Manning, G., & Malumbres, M. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16494 · Cited by 273
The Aurora B Kinase in Chromosome Bi-Orientation and Spindle Checkpoint Signaling
Krenn, V., & Musacchio, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00225 · Cited by 278
“One of the most exciting chapters in the study of Aurora B kinase has been the development of highly specific and selective chemical inhibitors, spurred by the identification of this kinase as a potential target in oncology (97).”
BackgroundPFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., Fedorov, O., Brennan, P., Bunnage, M. E., Owen, D. R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3292 · Cited by 249
“B-ALL primary graph NOD/Shi-scid/IL-2Rg (NOG) mice were engrafted with B-acute lymphoblastic leukemia (B-ALL) primary blasts t(1, 19)þ using a sample obtained from a 9-year-old child with high-risk B-ALL.”
Aurora kinase inhibitors: Progress towards the clinic
Kollareddy, M., Zheleva, D., Dzubak, P., Brahmkshatriya, P. S., Lepsik, M., & Hajduch, M. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9798-6 · Cited by 242
Döhner, H., Lübbert, M., Fiedler, W., Fouillard, L., Haaland, A., Brandwein, J. M., Lepretre, S., Reman, O., Turlure, P., Ottmann, O. G., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560557 · Cited by 231
“Standard 3/14 (21) 7/12 (58) Poor 3/30 (10) 6/30 (20)”
BackgroundKilling cells by targeting mitosis
Manchado, E., Guillamot, M., & Malumbres, M. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.197 · Cited by 228
“These two mitotic kinases are overexpressed in cancer cells, often correlating with worse prognosis, and their inhibition results in mitotic defects, making them attractive mitotic targets.(41,42) As previously reported for Eg5, disruption of Plk1 or Aurora A activity results in SAC-dependent mitotic arrest as a conse…”
BackgroundKomlodi-Pasztor, E., Sackett, D. L., & Fojo, A. T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0999 · Cited by 227
“inhibitors of KSP and PLK interfere with proper assembly of themitotic spindle and lead to arrest inmid-mitosis (4, 13).”
BackgroundTargeting the Mitotic Catastrophe Signaling Pathway in Cancer
Mc Gee, M. M. (2015) · Mediators of Inflammation · doi:10.1155/2015/146282 · Cited by 221
Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells
Ertych, N., Stolz, A., Stenzinger, A., Weichert, W., Kaulfuß, S., Burfeind, P., Aigner, A., Wordeman, L., & Bastians, H. (2014) · Nature Cell Biology · doi:10.1038/ncb2994 · Cited by 213
“…et al., 2009; Kaplan et al., 2001 Markowitz et al., 2009; Vogel et al., 2004 Markowitz et al., 2009; Luo et al., 2009 Weichert et al., 2005; Lens et al., 2010 Bischoff et al., 1998; Lens et al., 2010; this study CHK2 47% (loss) spindle assembly chromosomal instability Stolz et al., 2011;…”
BackgroundAurora-PLK1 cascades as key signaling modules in the regulation of mitosis
Joukov, V., & De Nicolo, A. (2018) · Science Signaling · doi:10.1126/scisignal.aar4195 · Cited by 209
“Consistent with this and with the role of PLK1 as a downstream effector of AurA and AurB, it was proposed that PLK1 has evolved also to control spindle MT–related processes, specifically MTOC formation and cytokinesis.”
BackgroundInfluentialMaire, V., Némati, F., Richardson, M., Vincent-Salomon, A., Tesson, B., Rigaill, G., Gravier, E., Marty-Prouvost, B., De Koning, L., Lang, G., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2633 · Cited by 194
“Polo-like kinase 1 (PLK1) is the best-characterized member of the human PLK family (PLK1-5) of serine/threonine protein kinases, which is involved in various functions such as mitotic entry, spindle assembly, and DNA damage response (8).”
BackgroundMitotic spindle multipolarity without centrosome amplification
Maiato, H., & Logarinho, E. (2014) · Nature Cell Biology · doi:10.1038/ncb2958 · Cited by 193
Aurora B kinase phosphorylates and instigates degradation of p53
Gully, C. P., Velazquez-Torres, G., Shin, J.-H., Fuentes-Mattei, E., Wang, E., Carlock, C., Chen, J., Rothenberg, D., Adams, H. P., Choi, H. H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110287109 · Cited by 189
“These small molecules can inhibit autophosphorylation of Aurora B and phosphorylation of histone H3 on Ser10 (7), but it is not clear how these small molecules can affect the uncharacterized functions of Aurora B.”
BackgroundTargeting pan-essential genes in cancer: Challenges and opportunities
Chang, L., Ruiz, P., Ito, T., & Sellers, W. R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.008 · Cited by 185
“AURKA and AURKB are amplified in several types of cancers, leading to the notion that they might make attractive cancer targets (Lens et al., 2010; Mehra et al., 2013).”
BackgroundSampson, P. B., Liu, Y., Forrest, B., Cumming, G., Li, S.-W., Patel, N. K., Edwards, L., Laufer, R., Feher, M., Ban, F., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5005336 · Cited by 173
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J., & Piccart, M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 178
Vallejo, A., Perurena, N., Guruceaga, E., Mazur, P. K., Martinez-Canarias, S., Zandueta, C., Valencia, K., Arricibita, A., Gwinn, D., Sayles, L. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14294 · Cited by 181
Yin, T., Wang, L., Yin, L., Zhou, J., & Huo, M. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.05.022 · Cited by 172
Yu, B., Yu, Z., Qi, P.-P., Yu, D.-Q., & Liu, H.-M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.020 · Cited by 171
“Among PLKs [14], PLK1 is the best characterized member with several inhibitors identified which are now in clinical/preclinical development [15e17].”
BackgroundPlk1 overexpression induces chromosomal instability and suppresses tumor development
de Cárcer, G., Venkateswaran, S. V., Salgueiro, L., El Bakkali, A., Somogyi, K., Rowald, K., Montañés, P., Sanclemente, M., Escobar, B., de Martino, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05429-5 · Cited by 167
ALIX and ESCRT-I/II function as parallel ESCRT-III recruiters in cytokinetic abscission
Christ, L., Wenzel, E. M., Liestøl, K., Raiborg, C., Campsteijn, C., & Stenmark, H. (2016) · Journal of Cell Biology · doi:10.1083/jcb.201507009 · Cited by 163
“The importance of correct cytokinetic abscission is most apparent in the presence of chromosome bridges traversing the intercellular bridge, whereby failure to coordinate abscission with removal of the physical impediment can lead to furrow regression and formation of tetraploid cells or premature scission in the pres…”
BackgroundDifferential network entropy reveals cancer system hallmarks
West, J., Bianconi, G., Severini, S., & Teschendorff, A. E. (2012) · Scientific Reports · doi:10.1038/srep00802 · Cited by 164
“…suggests that the closely related kinase, AURKB , which has already been implicated as an oncogene and potential drug target in other cancers (Lens et al. , 2010; Lucena-Araujo et al. , 2011; Morozova et al. , 2010), may also play an equally important role in the pathogenesis of bladder…”
BackgroundAn extensive program of periodic alternative splicing linked to cell cycle progression
Dominguez, D., Tsai, Y., Weatheritt, R. J., Wang, Y., Blencowe, B. J., & Wang, Z. (2016) · eLife · doi:10.7554/elife.10288 · Cited by 172
“Interestingly, one of these IR events is in transcripts encoding aurora kinase B (AURKB), a critical mitotic factor regulated at the levels of transcription, protein localization, phosphorylation and ubiquitination (Carmena et al., 2012; Lens et al., 2010).”
Cell cycle progression by the repression of primary cilia formation in proliferating cells
Goto, H., Inoko, A., & Inagaki, M. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1302-8 · Cited by 171
“Several binding proteins are known to regulate the localization, activation, and/or substrate preference of Aurora-A [42, 43].”
Tan, J. Y., Li, Z., Lee, P. L., Guan, P., Aau, M. Y., Lee, S. T., Feng, M., Lim, C. Z., Lee, E. Y. J., Wee, Z. N., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0595 · Cited by 152
Cell division control by the Chromosomal Passenger Complex
van der Waal, M. S., Hengeveld, R. C. C., van der Horst, A., & Lens, S. M. A. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.03.015 · Cited by 175
Self-citationWang, S. M., Ooi, L. L., & Hui, K. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0557 · Cited by 155
“6A), the major mechanism involved in cell division (30).”
BackgroundEspinosa-García, A. M., Alfaro, A., Román-Basaure, E., Guardado-Estrada, M., Lara, I. P., Serralde, C., Medina, I., Juárez, E., Bermúdez, M., Márquez, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055975 · Cited by 152
Logothetis, C. J., Gallick, G. E., Maity, S. N., Kim, J., Aparicio, A. M., Efstathiou, E., & Lin, S.-H. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0460 · Cited by 155
“Plk1 mediates entry into mitosis as well as centrosome maturation, spindle checkpoint activity, activation of the Anaphase-Promoting Complex (APC) and eventual exit from the M phase with the initiation of cytokinesis (85).”
BackgroundUnderstanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes
Aparicio, A. M., Logothetis, C. J., & Maity, S. N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0259 · Cited by 137
PIM1 kinase as a target for cancer therapy
Merkel, A. L., Meggers, E., & Ocker, M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.668527 · Cited by 133
“Small molecule inhibitors have been developed and tested in clinical trials for some members of this family, for example, the mTOR (mammalian target of rapamycin) complexes [8-10], polo-like kinases [11,12] or aurora kinases [13-15].”
BackgroundValsasina, B., Beria, I., Alli, C., Alzani, R., Avanzi, N. R., Ballinari, D., Cappella, P., Caruso, M., Casolaro, A., Ciavolella, A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0765 · Cited by 128
“intense efforts to identify and develop small-molecule inhibitors of PLK1 and indeed different compounds are currently under clinical investigation (19).”
BackgroundSakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., & Harashima, H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.57 · Cited by 124
Essential role for a novel population of binucleated mammary epithelial cells in lactation
Rios, A. C., Fu, N. Y., Jamieson, P. R., Pal, B., Whitehead, L. W., Nicholas, K. R., Lindeman, G. J., & Visvader, J. E. (2016) · Nature Communications · doi:10.1038/ncomms11400 · Cited by 145
on behalf of the DeCoDe PET group, Goos, J. A. C. M., Coupé, V. M. H., Diosdado, B., Diemen, P. M. D., Karga, C., Beliën, J. A. M., Carvalho, B. G., van den Tol, M. P., Verheul, H. M. W., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.608 · Cited by 125
“These inhibitors have demonstrated anticancer activity in various preclinical cancer models and some have entered clinical trials (Katayama and Sen, 2010; Lens et al, 2010; Cervantes et al, 2012).”
BackgroundEmerging roles of Aurora-A kinase in cancer therapy resistance
Zheng, D., Li, J., Yan, H., Zhang, G., Li, W., Chu, E., & Wei, N. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.03.013 · Cited by 128
Switching Polo-like kinase-1 on and off in time and space
Bruinsma, W., Raaijmakers, J. A., & Medema, R. H. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.09.005 · Cited by 125
Self-citationCho, H., Shimazu, T., Toyokawa, G., Daigo, Y., Maehara, Y., Hayami, S., Ito, A., Masuda, K., Ikawa, N., Field, H. I., et al. (2012) · Nature Communications · doi:10.1038/ncomms2074 · Cited by 122
“IB: HA (AURKB) HA–AURKB – – + – + – FLAG–AURKB-[1-200] FLAG–AURKB-[201-344]”
Fong, J. J., Nguyen, B. L., Bridger, R., Medrano, E. E., Wells, L., Pan, S., & Sifers, R. N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.315804 · Cited by 126
de Cárcer, G., Escobar, B., Higuero, A. M., Garcia, L. A. L., Ansón, A., Pérez, G., Mollejo, M., Manning, G., Meléndez, B., Abad‐Rodríguez, J., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.00607-10 · Cited by 119
“members may behave both as oncogenes and as tumor suppressors (30).”
BackgroundMELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells
Wang, Y., Lee, Y., Baitsch, L., Huang, A., Xiang, Y., Tong, H., Lako, A., Von, T., Choi, C. H., Lim, E., et al. (2014) · eLife · doi:10.7554/elife.01763 · Cited by 127
“Inhibiting them in cancer cells causes mitotic arrest and/or abnormalities in chromosome segregation and cytokinesis, which in turn trigger apoptosis (Taylor and Peters, 2008; Lens et al., 2010).”
BackgroundAurora Kinase A Promotes Inflammation and Tumorigenesis in Mice and Human Gastric Neoplasia
Katsha, A. M., Soutto, M., Sehdev, V., Peng, D., Washington, M. K., Piazuelo, M. B., Tantawy, M. N., Manning, H. C., Lu, P., Shyr, Y., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.050 · Cited by 120
Bub1 and BubR1: at the Interface between Chromosome Attachment and the Spindle Checkpoint
Elowe, S. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05326-11 · Cited by 126
Sampson, P. B., Liu, Y., Patel, N. K., Fehér, M., Forrest, B., Li, S.-W., Edwards, L. G., Laufer, R. S., Lang, Y., Ban, F., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500537u · Cited by 116
An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for Ependymoma
Atkinson, J. M., Shelat, A. A., Carcaboso, A. M., Kranenburg, T. A., Arnold, L. A., Boulos, N., Wright, K. D., Johnson, R. A., Poppleton, H., Mohankumar, K. M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.013 · Cited by 120
“…and PLK1 inhibitors, of which more than 18 are currently in Phase I or II clinical trial, are attractive candidates for ependymoma clinical trials (Lens et al., 2010; (C) ROC analyses showing the true (y axis) versus false (x axis) positive rates of p curves in gray are calculated from 200…”
Mitosis as an anti-cancer target
Janssen, A., & Medema, R. H. (2011) · Oncogene · doi:10.1038/onc.2011.30 · Cited by 137
Self-citationRNF4 and PLK1 are required for replication fork collapse in ATR-deficient cells
Ragland, R. L., Patel, S., Rivard, R. S., Smith, K. D., Peters, A. A., Bielinsky, A., & Brown, E. J. (2013) · Genes & Development · doi:10.1101/gad.223180.113 · Cited by 134
“CDK1–CYCB, AURKA, and PLK1 form a positive feedback circuit that leads ultimately to maximal activation of each kinase (Lens et al. 2010).”
BackgroundMethodInfluentialAurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle
Hochegger, H., Hégarat, N., & Pereira-Leal, J. B. (2013) · Open Biology · doi:10.1098/rsob.120185 · Cited by 112
“Detailed overviews of individual Aurora A and B structure, functions, interactions and activation mechanisms have been given in excellent recent reviews [15,16,48,49].”
BackgroundMethodAurora B Overexpression Causes Aneuploidy and p21 Cip1 Repression during Tumor Development
González‐Loyola, A., Fernández‐Miranda, G., Trakala, M., Partida, D., Samejima, K., Ogawa, H., Cañamero, M., Martino, A. D., Martínez‐Ramírez, Á., de Cárcer, G., et al. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01286-14 · Cited by 127
“Since Aurora kinases are currently considered important cancer targets (48, 49), our data also suggest a possible effect of Aurora inhibitors in restoring p53 activity at least in some specific tumors.”
BackgroundFernández‐Miranda, G., Trakala, M., Martin, J. J., Escobar, B., González‐Loyola, A., Ghyselinck, N. B., Ortega, S., Cañamero, M., de Castro, I. P., & Malumbres, M. (2011) · Development · doi:10.1242/dev.066381 · Cited by 122
Boeckx, C., Baay, M. F. D., Wouters, A., Specenier, P. M., Vermorken, J. B., Peeters, M., & Lardon, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0013 · Cited by 120
Mitotic catastrophe and cancer drug resistance: A link that must to be broken
Denisenko, T. V., Sorokina, I. V., Gogvadze, V., & Zhivotovsky, B. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.002 · Cited by 108
Haspin inhibitors reveal centromeric functions of Aurora B in chromosome segregation
Wang, F., Ulyanova, N. P., Daum, J. R., Patnaik, D., Kateneva, A. V., Gorbsky, G. J., & Higgins, J. M. G. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201205106 · Cited by 108
“Indeed, it is possible that coinhibition of Haspin and Aurora B will provide means to enhance the effects of Aurora B inhibitors currently in clinical trials (Lens et al., 2010), and a compound that inhibits Haspin has shown anti-tumor activity in a mouse xenograft model (Huertas et al.”
The Centrosome, a Multitalented Renaissance Organelle
Vertii, A., Hehnly, H., & Doxsey, S. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a025049 · Cited by 122
“Plk1 seems to be more specific and directly phosphorylates substrates required for centrosome maturation and spindle assembly proteins (reviewed by Lens et al. 2010).”
BackgroundA Comprehensive Bioinformatics Analysis of UBE2C in Cancers
Dastsooz, H., Cereda, M., Donna, D., & Oliviero, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092228 · Cited by 119
“These include members of the kinesin family (KIF20A, KIF18B, KIFC1, and KIF4A), with roles in mitotic spindle maintenance, chromosome segregation, and microtubule depolarization [32,33]; AURKB as a regulator of chromosome segregation during mitosis [34]; TROAP (a member of the cell adhesion molecule complex) with a ro…”
The Centrosome and the Primary Cilium: The Yin and Yang of a Hybrid Organelle
Joukov, V., & Nicolo, A. D. (2019) · Cells · doi:10.3390/cells8070701 · Cited by 112
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets
Palmieri, G., Ombra, M. N., Colombino, M., Casula, M., Sini, M. C., Manca, A., Paliogiannis, P., Ascierto, P. A., & Cossu, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00183 · Cited by 120
“Finally, both AurkA and AurkB associate with polo-like kinases and other additional partners crucial for oncogenic activity (162).”
BackgroundShi, W., Zhang, G., Ma, Z., Li, L., Liu, M., Qin, L., Yu, Z., Zhao, L., Liu, Y., Zhang, X. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23053-8 · Cited by 106
Ohoka, N., Nagai, K., Hattori, T., Okuhira, K., Shibata, N., Cho, N. J., & Naito, M. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.471 · Cited by 104
Cross-Talk between AURKA and Plk1 in Mitotic Entry and Spindle Assembly
Asteriti, I. A., Mattia, F. D., & Guarguaglini, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00283 · Cited by 99
Cell Cycle Control: A System of Interlinking Oscillators
Poon, R. Y. C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2957-3_1 · Cited by 116
Yuan, J., Sanhaji, M., Krämer, A., Reindl, W., Hofmann, M., Kreis, N., Zimmer, B., Berg, T., & Strebhardt, K. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.031 · Cited by 98
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
Donnella, H. J., Webber, J. T., Levin, R. S., Camarda, R., Momcilovic, O., Bayani, N., Shah, K. N., Korkola, J. E., Shokat, K. M., Goga, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0081-9 · Cited by 90
“1f) 16 .”
Mechanisms of ciliogenesis suppression in dividing cells
Goto, H., Inaba, H., & Inagaki, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2369-9 · Cited by 97
Li, Z., & Rana, T. M. (2012) · Nature Communications · doi:10.1038/ncomms2059 · Cited by 97
Bioorthogonal Imaging of Aurora Kinase A in Live Cells
Yang, K. S., Budin, G., Reiner, T., Vinegoni, C., & Weissleder, R. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201200994 · Cited by 89
Advancing Precision Medicine for Prostate Cancer Through Genomics
Roychowdhury, S., & Chinnaiyan, A. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3662 · Cited by 90
Ding, Y., Hubert, C. G., Herman, J., Corrin, P. D., Toledo, C. M., Skutt-Kakaria, K., Vazquez, J., Basom, R., Zhang, B., Risler, J. K., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0353 · Cited by 94
Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
Ali, H. R., Dawson, S.-J., Blows, F. M., Provenzano, E., Pd, P., & Caldas, C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.167 · Cited by 86
“As a protein, which functions specifically during mitosis, AURKA also represents an attractive drug target and several AURKA inhibitors are under development (Keen and Taylor, 2004; Lens et al, 2010).”
BackgroundTargeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors
Pitts, T. M., Davis, S. L., Eckhardt, S. G., & Bradshaw‐Pierce, E. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.010 · Cited by 94
Faisal, A., Vaughan, L. S., Bavetsias, V., Sun, C., Atrash, B., Avery, S., Jamin, Y., Robinson, S. P., Workman, P., Blagg, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0333 · Cited by 94
“The Aurora kinases are a family of highly conserved serine/threonine kinases that are important for faithful transition through mitosis (6-8).”
BackgroundRaab, M., Kappel, S., Krämer, A., Sanhaji, M., Matthess, Y., Kurunci‐Csacsko, E., Calzada‐Wack, J., Rathkolb, B., Rozman, J., Adler, T., et al. (2011) · Nature Communications · doi:10.1038/ncomms1395 · Cited by 85
CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression
Kong, Y., Yang, L., Wei, W., Lyu, N., Zou, Y., Gao, G., Ou, X., Xie, X., & Tang, H. (2019) · Epigenomics · doi:10.2217/epi-2019-0093 · Cited by 85
Isatin–azole hybrids and their anticancer activities
Hou, Y., Shang, C., Wang, H., & Yun, J. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201900272 · Cited by 88
Hamidi, T., Cano, C. E., Grasso, D., Garcia, M. N., Sandí, M. J., Calvo, E. L., Dagorn, J., Lomberk, G. A., Urrutia, R. A., Goruppi, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0026 · Cited by 85
“Such rationale was based on its effect on mitosis (46, 47) but results from this study provide an additional reason for its targeting.”
ResultPandolfi, S., & Stecca, B. A. (2015) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.3 · Cited by 91
Lu, Y., Yang, G., Xiao, Y., Zhang, T., Su, F., Chang, R., Ling, X., & Bai, Y. (2020) · Breast Cancer · doi:10.1007/s12282-020-01086-z · Cited by 84
Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
Hartsink-Segers, S. A., Zwaan, C. M., Exalto, C., Luijendijk, M. W. J., Calvert, V. S., Petricoin, E., We, E., Reinhardt, D., de Haas, V., Hedtjärn, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.256 · Cited by 82
Insights into the non-mitotic functions of Aurora kinase A: more than just cell division
Bertolin, G., & Tramier, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03310-2 · Cited by 88
“Given the fact that AURKA and AURKB show similar consensus phosphorylation motifs [48, 49], this FRET biosensor can be considered as a general reporter of the activity of both AURKA and AURKB, with a specificity towards AURKA or AURKB according to the localisation of the biosensor.”
BackgroundHikichi, Y., Honda, K., Hikami, K., Miyashita, H., Kaieda, I., Murai, S., Uchiyama, N., Hasegawa, M., Kawamoto, T., Sato, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0762 · Cited by 81
“PLK1 inhibitors are being evaluated in registered clinical trials (4).”
BackgroundCentrosome dynamics as a source of chromosomal instability
Nam, H.-J., Naylor, R. M., & van Deursen, J. M. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.10.002 · Cited by 83
Das, T., Roy, K. S., Chakrabarti, T., Mukhopadhyay, S., & Roychoudhury, S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.022 · Cited by 79
Yang, D., Yang, Y., Zhou, Y., Yu, L., Wang, R., Di, B., & Niu, M. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201904969 · Cited by 84
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity
Wright, G., Golubeva, V., Remsing Rix, L. L., Berndt, N., Luo, Y., Ward, G. A., Gray, J. E., Schonbrunn, E., Lawrence, H. R., Monteiro, A. N. A., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00147 · Cited by 77
Recent contributions of quinolines to antimalarial and anticancer drug discovery research
de Walle, T. V., Cools, L., Mangelinckx, S., & D’hooghe, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113865 · Cited by 86
Lee, C., Fotovati, A., Triscott, J., Chen, J. Y., Venugopal, C., Singhal, A., Dunham, C. P., Kerr, J. M., Verreault, M., Yip, S. S. F., et al. (2012) · Stem Cells · doi:10.1002/stem.1081 · Cited by 78
Hammond, D. E., Zeng, K., Espert, A., Bastos, R. N., Baron, R. D., Grüneberg, U., & Barr, F. A. (2013) · Journal of Cell Science · doi:10.1242/jcs.128397 · Cited by 91
“Early pre-clinical investigations of Aurora-A and Aurora B kinase inhibitors have demonstrated promising results and phase I/II trials investigating a number of these compounds are underway (Lens et al., 2010).”
BackgroundInfluential
Metadata
- Authors
- Lens, S. M. A., Voest, E. E., & Medema, R. H.
- Affiliations
- University Medical Center Utrecht (NL)
- Corresponding author
- Lens, Susanne M. A.
- Medema, René H.
- Venue
- Nature Reviews Cancer
- Published
- 2010-11-24
- Volume
- 10
- Issue
- 12
- Pages
- 825-841
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1994488152
- Cited by
- 597
- References
- 227
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 10 · 2023: 28 · 2022: 24 · 2021: 29 · 2020: 42 · 2019: 37 · 2018: 27 · 2017: 33 · 2016: 36 · 2015: 56 · 2014: 59 · 2013: 64 · 2012: 65
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- Polo-like kinase, Aurora kinases, PLK1, AURKA, Aurora B kinase, mitosis, kinase inhibitors, anticancer agents, off-target effects, chemosensitization, targeted therapy
- MeSH terms
- Polo-Like Kinase 1, Animals, Chromatids, Humans, Mitosis, Neoplasms, Proto-Oncogene Proteins, Protein Serine-Threonine Kinases, Kinetochores, Cell Cycle Proteins, Protein Kinase Inhibitors, Cytokinesis, Aurora Kinase A, Aurora Kinase B, Aurora Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.